Cytomegalovirus clinical trials at UC Davis

• Experimental Letermovir (LET) to Prevent Cytomegalovirus (CMV) Infection After Stem Cell Transplant

  open to eligible people ages 18 years and up

  The purpose of this study is to evaluate the safety and efficacy of letermovir (LET) versus placebo when extended from 100 days to 200 days post-transplant in cytomegalovirus (CMV) seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It is hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.

  Sacramento, California and other locations

Last updated: November 3, 2021